
Hydrogel Particle-Based Microrna Profiling for Discovery and Cancer DiagnosticsAward last edited on: 12/12/18
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$1,975,082Award Phase
2Solicitation Topic Code
-----Principal Investigator
Daniel C PregibonCompany Information
Firefly BioWorks Inc (AKA: Elucigel Technologies)
1 Kendall Square Building 1400w 3rd Floor
Cambridge, MA 02139
Cambridge, MA 02139
(617) 500-6247 |
info@fireflybio.com |
www.fireflybio.com |
Location: Single
Congr. District: 07
County: Middlesex
Congr. District: 07
County: Middlesex
Phase I
Contract Number: 1R43CA141980-01Start Date: 9/1/09 Completed: 8/28/10
Phase I year
2009Phase I Amount
$249,885Public Health Relevance:
The aim of this project is to develop a technology capable of profiling across all human microRNA in a manner that is accurate, rapid, and inexpensive. This tool will be enabling for cancer research, drug discovery, and cancer diagnostics.
Public Health Relevance Statement:
The aim of this project is to develop a technology capable of profiling across all human microRNA in a manner that is accurate, rapid, and inexpensive. This tool will be enabling for cancer research, drug discovery, and cancer diagnostics.
Project Terms:
1,2-Ethanediol; 2-Hydroxyethanol; Arts; Assay; Binding; Binding (Molecular Function); Bioassay; Biologic Assays; Biological Assay; Body Tissues; Brain; Cancer Detection; Cancer Diagnostics; Cancerous; Cancers; Cardiac Diseases; Cardiac Disorders; Clinical; Clinical Trials, Phase II; Code; Coding System; Data; Detection; Diabetes Mellitus; Diagnosis; Diagnostic; Dihydroxyethanes; Disease; Disorder; Down-Regulation; Down-Regulation (Physiology); Downregulation; Embryonic Tissue, Placenta; Encephalon; Encephalons; Ethanediols; Ethylene Glycols; Expression Profiling; Expression Signature; Future; Gene Products, RNA; Goals; Heart Diseases; High Throughput Assay; Human; Human, General; Hydrogels; Intention; Kinetic; Kinetics; Label; Lung; Malignant Neoplasms; Malignant Tumor; Man (Taxonomy); Man, Modern; Marketing; Micro RNA; MicroRNAs; Molecular Fingerprinting; Molecular Interaction; Molecular Profiling; Monoethylene Glycol; Nature; Nervous System, Brain; Nucleotides; Performance; Phase; Phase 2 Clinical Trials; Phase II Clinical Trials; Placenta; Placenta-Tissue, Cells; Placentoma, Normal; Placentome; RNA; RNA, Non-Polyadenylated; Reproducibility; Research; Respiratory System, Lung; Ribonucleic Acid; SBIR; SBIRS (R43/44); Sampling; Scanning; Scheme; Screening procedure; Sensitivity and Specificity; Sequence Homology; Small Business Innovation Research; Small Business Innovation Research Grant; Solutions; Specificity; Speed; Speed (motion); Stream; Structure; System; System, LOINC Axis 4; Targeted Research; Technology; Testing; Thermodynamic; Thermodynamics; Tissues; anticancer research; base; cancer research; cost; diabetes; disease/disorder; drug discovery; ethylene glycol; heart disorder; high throughput screening; homology (molecular); human tissue; malignancy; miRNA; molecuar profile; molecular signature; neoplasm/cancer; particle; phase 2 study; phase 2 trial; phase II trial; protocol, phase II; public health relevance; pulmonary; screening; screenings; study, phase II; success; tool
Phase II
Contract Number: 2R44CA141980-02A1Start Date: 00/00/00 Completed: 00/00/00
Phase II year
2011(last award dollars: 2012)
Phase II Amount
$1,725,197Public Health Relevance:
The aim of this project is to develop a technology capable of profiling across all human microRNA in a manner that is accurate, rapid, and inexpensive. This tool will be enabling for cancer research, drug discovery, and cancer diagnostics.
Public Health Relevance Statement:
The aim of this project is to develop a technology capable of profiling across all human microRNA in a manner that is accurate, rapid, and inexpensive. This tool will be enabling for cancer research, drug discovery, and cancer diagnostics.
NIH Spending Category:
Bioengineering; Biotechnology; Cancer; Genetics
Project Terms:
Alzheimer's Disease; anticancer research; base; Biological Assay; Cancer Diagnostics; cancer type; Cells; Clinical; Collaborations; commercialization; Comparative Study; Complementary DNA; Custom; Cytolysis; density; design; Detection; Devices; Diabetes Mellitus; Diagnosis; Discrimination (Psychology); Disease; drug discovery; Ensure; experience; Fireflies; Functional RNA; Gel; Genes; Goals; Heart Diseases; high throughput screening; Hour; Human; Hydrogels; Label; Laboratories; Leukemia, Myelocytic, Acute; Liquid substance; Literature; lithography; Malignant Neoplasms; meetings; MicroRNAs; Molecular Profiling; National Cancer Institute; Nucleic Acids; Nucleotides; Optics; particle; Patients; Performance; Phase; phase 1 study; phase 2 study; professor; prototype; Research; RNA; RNA purification; Sampling; scale up; Scanning; Scheme; Sequence Homology; Serum; Specificity; Structure; success; System; Technology; tool; Validation; Variant; Work